How CJC-1295 No-DAC Affects Cortisol

CJC-1295 no-DAC (modified GRF 1-29) is a structurally modified fragment of endogenous GHRH. Its mechanism is confined to the GHRH receptor:

1. GHRH receptor specificity: CJC-1295 no-DAC binds only the GHRH-R on anterior pituitary somatotrophs. GHRH-R activation signals exclusively through cAMP-PKA pathways that promote GH synthesis and secretion. The GHRH-R pathway has no documented cross-talk with the CRH-ACTH-cortisol axis.
2. HPA axis independence: Cortisol secretion is regulated by the CRH (corticotropin-releasing hormone) / ACTH (adrenocorticotropic hormone) axis, which is entirely separate from the GHRH / GH axis at the pituitary level. Activation of somatotrophs by GHRH does not trigger corticotrophs to release ACTH.
3. Contrast with ghrelin-receptor agonists: GHRP-6, GHRP-2, and hexarelin all activate the GHS-R1a ghrelin receptor, which has functional expression in the hypothalamus and pituitary corticotrophs. At clinical doses, these peptides stimulate ACTH and cortisol release as a direct pharmacological side effect. CJC-1295 no-DAC, as a GHRH analog rather than a GHS-R1a agonist, does not share this mechanism.
4. Ipamorelin's cortisol selectivity reinforces the stack: When CJC-1295 no-DAC is combined with ipamorelin (the standard protocol), the cortisol-neutral profile of both components is additive. Raun et al. (1998, PMID 9849822) confirmed that ipamorelin does not elevate ACTH or cortisol at doses up to 200 times the effective GH dose. The combination therefore produces GH and IGF-1 elevation without HPA axis activation.

No published human trial has directly measured cortisol during CJC-1295 no-DAC use. The mechanistic evidence and the cortisol-neutral profile of tesamorelin (a related GHRH analog) support the expectation of no cortisol effect.

Standard combined protocol (100 mcg CJC-1295 no-DAC + 200-300 mcg ipamorelin, 1-2 times daily):

• Cortisol: no change expected; mechanistically excluded by GHRH-R specificity
• ACTH: no change expected
• Morning cortisol on a standard blood panel: normal (typically 6 to 23 mcg/dL or 170 to 635 nmol/L)

Contrast with cortisol-elevating GHRPs:

• GHRP-6 at 1 mcg/kg IV: raises cortisol by approximately 50 to 80% above baseline within 30 minutes (Arvat et al., 1997, PMID 9285939)
• GHRP-2 and hexarelin: similar cortisol elevations documented in multiple studies
• Ipamorelin at 200x effective GH dose: no significant cortisol elevation (Raun et al., 1998, PMID 9849822)
• CJC-1295 no-DAC: expected to share ipamorelin's cortisol-neutral profile based on distinct GHRH-R mechanism

Routine cortisol monitoring is not required for CJC-1295 no-DAC protocols. There is no mechanistic basis for cortisol disruption from GHRH-R activation.

When to check cortisol:

• If symptoms of HPA axis disruption appear: unexplained fatigue, salt craving, low blood pressure, skin hyperpigmentation, morning nausea. These suggest a separate issue unrelated to CJC-1295 no-DAC.
• If transitioning from a cortisol-elevating GHRP (GHRP-6, GHRP-2, hexarelin) to the ipamorelin plus CJC-1295 no-DAC stack, a baseline cortisol 4 to 6 weeks post-transition can confirm the expected normalisation.
• If stacking with compounds known to suppress cortisol (exogenous glucocorticoids) or elevate cortisol (high-dose trenbolone via MR agonism), monitor cortisol for the confounding compound rather than CJC-1295 no-DAC.

No cortisol-specific interventions are required for CJC-1295 no-DAC users.

If switching from a cortisol-elevating GHRP:

• Users transitioning from GHRP-6 or hexarelin to the CJC-1295 no-DAC plus ipamorelin stack can expect cortisol levels to normalise within 2 to 4 weeks
• The perceived improvements in recovery, mood, and sleep quality sometimes reported when switching from non-selective GHRPs to ipamorelin are mechanistically consistent with cortisol normalisation

Stacking considerations:

• Adding CJC-1295 no-DAC to a stack already containing trenbolone (mild MR agonist) or corticosteroids does not add cortisol load from the peptide itself
• No phosphatidylserine or cortisol-modulating supplementation is needed specifically for CJC-1295 no-DAC